Last week, the Drug Enforcement Administration (DEA) said opioid treatment programs (OTPs) and Drug Addiction Treatment Act (DATA)--waived prescribers can treat new patients with buprenorphine based on a telephone call only. The Controlled Substances Act (CSA), enforced by the DEA, requires all new patients being treated with controlled substances to have an in‐person --- or, for now, telemedicine --- physical exam. Now, however, because of the coexisting COVID‐19 pandemic and opioid overdose crisis, the DEA has dropped this requirement. This follows the decision of the Substance Abuse and Mental Health Services Administration (SAMHSA) to allow exemptions from the OTP take‐home regulations allowing stable patients to be given 14 or 28 days of methadone doses, instead of coming in more frequently (see DEA, SAMHSA relax OTP/OBOT regulations due to COVID‐19, *ADAW* March 23, <https://onlinelibrary.wiley.com/doi/10.1002/adaw.32664>).

The move also follows the DEA\'s ruling that the Ryan Haight Act, which requires in‐person physical exams, is temporarily not being enforced, and instead allows these exams to be done by telemedicine. Now, all that is needed for new buprenorphine patients is a phone call.

"Under normal circumstances, DEA would not consider the initiation of treatment with a controlled substance based on a mere phone call to be consistent with the framework of the CSA given that doing so creates a high risk of diversion," the March 31 statement said. "However, in light of the extraordinary circumstances presented by the COVID‐19 public health emergency, and being mindful of the exemption issued by SAMHSA, DEA likewise advises that, only for the duration of the public health emergency (unless DEA specifies an earlier date), OTPs should feel free to dispense, and DATA‐waived practitioners should feel free to prescribe, buprenorphine to new patients with OUD \[opioid use disorder\] for maintenance treatment or detoxification treatment following an evaluation via telephone voice calls, without first performing an in‐person or telemedicine evaluation. This may only be done, however, if the evaluating practitioner determines that an adequate evaluation of the patient can be accomplished via the use of a telephone." "**"...DATA‐waived practitioners should feel free to prescribe, buprenorphine to new patients with OUD \[opioid use disorder\] for maintenance treatment or detoxification treatment following an evaluation via telephone voice calls, without first performing an in‐person or telemedicine evaluation."**DEA"

The phone exam {#adaw32680-sec-0002}
==============

The physical exam would be done on the phone. Exactly how that is done is not clear, but Zachary Talbott, chief clinical officer with ReVIDA Recovery Centers and president of the National Alliance for Medication Assisted Recovery, said it is not a problem. "We can still assess impairment with voice," he told *ADAW*. "It\'s just not as thorough." And providers still check the prescription drug monitoring program. "We are working very hard to ensure as much quality and as many controls as possible," he said.

It has never been so important to treat opioid use disorder, said Talbott. "In addition to the normal risks of overdose, HIV, hepatitis C, violence, we now have the risk of COVID‐19," he said. What about having nonclinicians who aren\'t trained make such decisions? "What if we don\'t?" asked Talbott. "What are the societal consequences of folks going out seeking drugs during a time of social distancing?"

The exam would be done the same way it is in person, or via telemedicine, said Talbott. Is there a recommended script for what to ask prospective patients who want buprenorphine called in for the first time? "We don\'t treat patients via script," said Talbott. "That isn\'t treatment. Physicians document everything they would otherwise." This includes a history of the present illness, and review of as many systems as they can without the patient being present. "Document that this was during COVID‐19 and why in‐person wasn\'t possible," he said. Talbott added that "counselors still do a full psychosocial assessment and develop a treatment plan."

As for concerns about buprenorphine supply, this should not be an issue, said Talbott. "The pharmacists and drug company people I\'ve spoken with aren\'t concerned about supplies," he said. "Supplies of other sedatives are a real issue for folks on respiratory and such," he said, noting the "villainization by the opioid crisis." The chief pharmacist in Tennessee, where Talbott is located, and his personal contact at Indivior assured him that supplies are not something to worry about, he said. "And they said if we hear issues, to let them know and they will help," he added.

Meanwhile, at NYU Langone, treatment providers immediately started advertising the availability of buprenorphine‐by‐phone. Joshua Lee, M.D., associate professor of population health and director of the NYU Fellowship in Addiction Medicine, explained to *ADAW* that patients will be expected to come in later in‐person, but for now, the assessment can be done on the phone -- of course with checking the state\'s prescription monitoring program to make sure the caller isn\'t already getting other medications that would conflict. Before the DEA\'s announcement, clinicians had been planning on using Zoom for intakes and phone for followup.

Many people hope these changes are here to stay. "It is great to see how policies can change to overcome barriers," said Kathryn Cates‐Wessel, CEO of the American Academy of Addiction Psychiatry (AAAP). "Let\'s hope they stick for the long haul."

Representatives of the American Society of Addiction Medicine and others in the field told ADAW there was "too much going on" to comment by press time ‐‐ April 1 ‐‐ on the March 31 DEA policy. Talbott said the telephone policy is "right and just," adding "it\'s the path of the least harm during an unprecedented national emergency."

Not a law {#adaw32680-sec-0003}
=========

It should be noted that the DEA policy is not the same as a law. Here\'s the caveat:

"Guidance documents, like this document, are not binding on the public and lack the force and effect of law, unless expressly authorized by statute or expressly incorporated into a contract, grant, or cooperative agreement. Consistent with Executive Order 13891 and the Office of Management and Budget implementing memoranda, the Department will not cite, use, or rely on any guidance document that is not accessible through the Department\'s guidance portal, or similar guidance portals for other Executive Branch departments and agencies, except to establish historical facts. To the extent any guidance document sets out voluntary standards (e.g., recommended practices), compliance with those standards is voluntary, and noncompliance will not result in enforcement action. Guidance documents may be rescinded or modified in the Department\'s complete discretion, consistent with applicable laws."

Indivior declined to respond, which makes sense, as this is an off‐label use of the drug.

For the policy, go to <https://www.samhsa.gov/sites/default/files/dea-samhsa-buprenorphine-telemedicine.pdf>.
